Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Mar 25, 2030compositionUS 89808733.6y
Jan 17, 2029compositionUS 81536322.4y
May 5, 2028method-of-use (U-3331)US 95739641.7y

FDA exclusivities (2)

Feb 28, 2029ODE-397Orphan Drug (7y)2.5y
Feb 28, 2027NCENew Chemical Entity (5y)193d

News(1)

Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
Sobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.
fiercebiotech · 8d ago

Data sources

openFDA · ClinicalTrials.gov

last refreshed 12m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

pacritinib

Marketedupdated 3mo ago

by Sobi Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 3

all catalysts(6)

approval · 6

Feb 28, 2022

approval

4y ago

VONJO (PACRITINIB CITRATE) — FDA approval

VONJO (PACRITINIB CITRATE) — FDA approval

VONJO (PACRITINIB CITRATE) — FDA approval

VONJO (PACRITINIB CITRATE) — FDA approval

VONJO (PACRITINIB CITRATE) — FDA approval

VONJO (PACRITINIB CITRATE) — FDA approval

pacritinib

→

Trials studying pacritinib

phase2Pacritinib in CMMLrecruitingn=26
phase1Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndromerecruitingn=15
phase2Pacritinib With Aza for Upfront Myelodysplastic Syndromenot yet recruitingn=25
phase2A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)recruitingn=78
phase2A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppressioncompletedn=40
phase2Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopeniasnot yet recruitingn=26
phase2Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemiarecruitingn=66
phase2Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasmsrecruitingn=27

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 28, 2027

193 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Mar 25, 2030compositionUS 89808733.6y
Jan 17, 2029compositionUS 81536322.4y
May 5, 2028method-of-use (U-3331)US 95739641.7y

FDA exclusivities (2)

Feb 28, 2029ODE-397Orphan Drug (7y)2.5y
Feb 28, 2027NCENew Chemical Entity (5y)193d

News(1)

Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
Sobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.
fiercebiotech · 8d ago

Data sources

openFDA · ClinicalTrials.gov

last refreshed 12m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

pacritinib

🐶 often sniffed alongside

all catalysts(6)

Trials studying pacritinib

Patent cliff

patents (3)

FDA exclusivities (2)

News(1)

Report a data issue

comments(0)

pacritinib

🐶 often sniffed alongside

all catalysts(6)

Trials studying pacritinib

Patent cliff

patents (3)

FDA exclusivities (2)

News(1)

Report a data issue

comments(0)